References
- Kosten T O, Rounsaville B J, Kleber H D. A 2.5 year follow-up of cocaine use among treated opioid addicts: have our treatments helped?. Arch Gen Psychiatry 1987; 44: 281–287
- Gawin F H, Ellinwood E H. Cocaine and other stimulants: actions, abuse, and treatment. N Engl J Med 1988; 318: 1173–1182
- Kosten T R. Pharmacotherapeutic interventions for cocaine abuse: matching patients to treatments. J Nerv Ment Dis 1989; 177: 379–389
- Oackis C A, Gold M S, Sweeney D R et al. Single-dose bromocriptine reverses cocaine craving. Psychiatry Res 1987; 20: 261–264
- Tennant F S, Sagherian A A. Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. Arch Intern Med 1987; 147: 109–112
- Kosten T R, Morgan C M, Falcioni J et al. Pharmacotherapy for cocaine abusing methadone maintained patients using amantadine or desipramine. Arch Gen Psychiatry 1992; 49: 894–899
- Weddington W W, Brown B S, Haertzen C A et al. Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am J Drug Alcohol Abuse 1991; 17: 137–152
- Margolin A, Kosten T R, Petrakis I et al. Bupropion reduces cocaine abuse in methadone maintained patients (letter). Arch Gen Psychiatry 1991; 48: 87
- Gawin F H, Riordan C, Kleber H D. Methylphenidate use in non-ADD cocaine abusers: a negative report. Am J Drug Alcohol Abuse 1985; 11: 193–197
- Ritz M C, Lamb R J, Goldberg S R et al. Cocaine receptors on dopamine transporters are related to cocaine self-administration. Science 1987; 238: 1219–1223
- Javitch J A, Blaustein R O, Snyder S H. (3H)-mazindol binding associated with neuronal dopamine and norepinephrine uptake sites. Mot Pharmacol 1984; 26: 35–44
- Chart L D, Uhlenhuth E H, Johanson C E. Reinforcing and subjective effects of several anorectics in normal human volunteers. J Pharmacol Exp Ther 1987; 242: 777–783
- Berger S P, Gawin F H, Kosten T R. Treatment of cocaine abuse with mazindol Getter. Lancet 1989; 1: 283
- Pickworth W B, Klein S A, Bunker E B et al. Assessment of mazindol for abuse liability, in Proceedings of the Committee on Problems of Drug Dependence 1990, L Harris, MD Rockville. NIDA Res Monogr 105, National Institute on Drug Abuse. 1991; 443
- Vonesh E F, Schork M A. Sample sizes in the multivariate analysis of repeated measurements. Biometrics 1986; 42: 601–610
- Kosten T R, Schumann B, Wright D et al. A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients. J Clin Psychiatry 1987; 48: 442–444
- Bruera E, Carraro S, Roca E et al. Double-blind evaluation of the effects of mazindol on pain, depression, anxiety, appetite, and activity in terminal cancer patients. Cancer Treat Rev 1986; 70: 295–298
- Miach P J, Thomson W, Doyle A E et al. Double blind cross-over evaluation of mazindol in die treatment of obese hypertensive patients. Med J Aust 1976; 2: 378–380
- Schindler J, Schachter M, Brincat S et al. Amphetamine, mazindol, and fencamfamin in narcolepsy. BMJ 1985; 290: 1167–1170
- Inoue S, Egawa M, Satoh S et al. Clinical and basic aspects of an anorexiant, mazindol, as an antiobeity agent in Japan. AmJ Clin Nutr 1992; 55: 199s
- Deiwaid P J, Martinelli P, Schoenen J. Mazindol in the treatment of Parkinson's disease. Arch Neurol 1983; 40: 788–790